Merus Labs International Inc. (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women's health and anti-infectives. Its products include Factive, Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.